THESIS — Prolium Bioscience is positioned to capture value in the crowded immuno-oncology space by advancing a rationally designed bispecific antibody that co-targets TIGIT and PVRIG to overcome primary resistance in solid tumors.
THE SCIENCE — The company's lead asset, PLB-101, is a humanized IgG bispecific antibody engineered to simultaneously block TIGIT and PVRIG, two co-inhibitory receptors expressed on tumor-infiltrating T cells and NK cells. The dual mechanism is critical: preclinical models show that single-agent TIGIT blockade is often circumvented by upregulation of the PVRIG pathway, particularly in cold tumors like non-small cell lung cancer and ovarian cancer. By blocking both pathways, PLB-101 aims to more potently reinvigorate the anti-tumor immune response.
WHY NOW — This $50M venture round is timed to fund a Phase 1b/2 trial of PLB-101 in combination with a PD-1 inhibitor, with initial monotherapy safety data already in hand. The capital will propel the program into expansion cohorts in selected PD-1/PD-L1 refractory populations, where the first meaningful efficacy signals for this novel mechanism are expected within 18 months.
THE CAPITAL — The $50M Series B, while led by undisclosed investors, follows a strategic seed round from a syndicate of top-tier life science VCs known for deep immuno-oncology expertise. The round's size and structure suggest conviction in the preclinical package and the initial clinical safety profile.
RISK/REWARD — The key risk is clinical: the TIGIT class has seen high-profile setbacks, and proving that dual targeting meaningfully improves outcomes over single agents is a high bar. The upside, however, is a multi-billion dollar opportunity; success in a defined refractory population could establish PLB-101 as a backbone combination therapy and make Prolium a compelling acquisition target for a large pharma seeking to bolster its IO portfolio.